Skip to main content Accessibility help
×
Home

Progress Report on the Canadian Multicentre Trial of Tetrahydroaminoacridine with Lecithin in Alzheimer's Disease

  • S. Gauthier (a1), R. Bouchard (a1), Y. Bacher (a1), P. Bailey (a1), H. Bergman (a1), L. Carrier (a1), R. Charbonneau (a1), M. Clarfield (a1), B. Collier (a1), D. Dastoor (a1), L. Gauthier (a1), M. Germain (a1), M. Kissel (a1), M. Krieger (a1), S. Kushnir (a1), A. Lamontagne (a1), J. Morin (a1), N.P.V. Nair (a1), L. Neirinck (a1), J. Ratner (a1), M. St-Martin (a1), S. Suissa (a1) and Y. Tesfaye (a1)...

Abstract:

Since the discovery of a significant depletion of acetylcholine in discrete areas of the brain of patients affected by Alzheimer's disease, attempts at symptomatic therapy have concentrated on acetylcholine supplementation, an approach that is based upon the efficacy of dopaminergic supplementation therapy for Parkinson's disease. Choline, then lecithin, used orally, failed to improve symptoms but the hypothesis that long-term choline supplementation might stabilize the course of Alzheimer's disease remains to be tested. Nerve growth factor may also offer that possibility. Bethanechol administered intracerebroventricularly did not help when a fixed dose was used but individual titration of more selective muscarinic agonists may prove more effective. In this article we report that tetrahydroaminoacridine (THA), given together with highly concentrated lecithin, appears to bring improvement in cognition and in functional autonomy using the Mini Mental State and the Rapid Disability Rating Scale-2 respectively, without change in behavior as reflected by the Behave-AD. Double-blind cross-over studies are in progress to establish its efficacy. Improvement in study design and means of assessment of cognition, functional autonomy and behavior have been made possible by these drug trials.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Progress Report on the Canadian Multicentre Trial of Tetrahydroaminoacridine with Lecithin in Alzheimer's Disease
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Progress Report on the Canadian Multicentre Trial of Tetrahydroaminoacridine with Lecithin in Alzheimer's Disease
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Progress Report on the Canadian Multicentre Trial of Tetrahydroaminoacridine with Lecithin in Alzheimer's Disease
      Available formats
      ×

Copyright

Corresponding author

McGill Centre for Studies in Aging, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4

References

Hide All
1.Etienne, P, Gauthier, S, Johnson, G, et al. Clinical effects of choline in Alzheimer–s disease. Lancet 1978; 1: 508.
2.Etienne, P, Dastoor, D, Gauthier, S, et al. Alzheimer disease: Lack of effect of lecithin treatment for 3 months. Neurology 1981; 31: 15521554.
3.Harbaugh, RE, Roberts, DW, Coombs, DW, et al. Preliminary report: Intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery 1984; 15: 514518.
4.Harbaugh, RE, Reeder, TM, Senter, HJ, et al. Intracerebroventricular bethanechol chloride infusion in Alzheimer–s disease: Results of a collaborative, double-blind study. J Neurosurg (in press).
5.Bouchard, R, Gauthier, L, Gauthier, S, et al. Intracerebroventricular bethanechol chloride in Alzheimer’s disease: Dose-related response in a patient. Can J Neurol Sci 1988; 15: 229330.
6.Summers, WK, Majoveski, LV, Marsh, GM, et al. Oral THA in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986; 315: 12411245.
7.Gauthier, S, Masson, H, Gauthier, L, et al. Tetrahydroaminoacridine and lecithin in Alzheimer’s disease. In: Giacobini, E, Becker, R, eds. Current Research in Alzheimer Therapy. New York: Taylor and Francis, 1988: 237245.
8.McKhann, G,Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: Report of the N1NCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939944.
9.Reisberg, B, Ferris, SH, De Leon, MJ, et al. The global deterioration scale (GDS): An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982; 139: 11361139.
10.Rosen, WG, Terry, RD, Fuld, PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1979; 7: 486488.
11.NIH Consensus Conference. Differential diagnosis of dementing diseases. JAMA 1987; 258: 34113416.
12.Folstein, MF, Folstein, SE, McHugh, PR. “Mini Mental State” A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189198.
13.Teng, EL, Chui, HC. The modified Mini Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314318.
14.Linn, MW, Linn, BS. The rapid disability rating scale-II. J Am Geriatr Soc 1982; 30: 378382.
15.Reisberg, B, Borenstein, J, Salob, SP, et al. Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry 1987; 48: 5 [suppl]: 915.
16.Cole, M, Dastoor, D, Koszycki, DThe hierarchic dementia scale. J Clin Exp Gerontol 1983; 3: 219234.

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed